Bausch & Lomb Corp
Company Profile
Business description
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Contact
520 Applewood Crescent
VaughanONL4K 4B4
CANT: +1 905 695-7700
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,500
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
stocks
Why Guzman and Reece's share reversals have a lot in common
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,477.30 | 20.70 | -0.24% |
CAC 40 | 8,143.92 | 92.85 | 1.15% |
DAX 40 | 22,794.11 | 383.84 | 1.71% |
Dow JONES (US) | 43,411.68 | 49.53 | -0.11% |
FTSE 100 | 8,706.59 | 37.92 | 0.44% |
HKSE | 23,787.93 | 753.91 | 3.27% |
NASDAQ | 19,035.38 | 8.99 | 0.05% |
Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
S&P 500 | 5,948.96 | 6.29 | -0.11% |
S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
SSE Composite Index | 3,380.21 | 34.17 | 1.02% |